Ironwood Pharma (IRWD) Receives a Hold from H.C. Wainwright

By Jason Carr

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Ironwood Pharma (IRWDResearch Report), with a price target of $14. The company’s shares closed on Friday at $11.48.

Selvaraju noted:

“We utilize a discounted cash flow (DCF)-based approach, which yields a total risk-adjusted net present value (rNPV) of $2.4B, of which roughly $1.95B is based on Ironwood’s ownership stake in linaclotide. The remainder consists of our $450M rNPV for IW-3718, to which we ascribe a 40% probability of approval.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 0.9% and a 38.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Ironwood Pharma is a Moderate Buy with an average price target of $16.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.74 and a one-year low of $7.59. Currently, Ironwood Pharma has an average volume of 1.5M.

Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is neutral on the stock. Most recently, in January 2019, Halley Gilbert, the Chief Admin Officer & SVP of IRWD bought 20,449 shares for a total of $99,996.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F.